MagForce AG Installs NanoActivator(R) at the Cologne University Hospital

BERLIN & NEVADA--(BUSINESS WIRE)-- MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fourth NanoActivator(R). The device was installed at Cologne University Hospital to provide NanoTherm(TM) therapy for the treatment of brain cancers and Cologne University Hospital will participate in MagForce's post marketing study. Since NanoTherm(TM) therapy has the European CE mark (in the 27 EU countries), commercial patients can also be treated in Cologne. NanoActivator(R) devices are now available for treatment of patients at the University Medical Centers in Cologne, Kiel, Münster and Berlin.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Language: English

Company: MagForce AG Max-Planck-Straße 3 12489 Berlin Germany

Phone: +49 (0)30 308 380 0

Fax: +49 (0)30 308 380 99

E-mail: [email protected]

Internet: www.magforce.com

ISIN: DE000A0HGQF5 WKN: A0HGQF

Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt

Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: [email protected]

Source: MagForce AG

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study
• Zoom Appoints Former Oracle CFO Jeff Epstein to Board of Directors; Jonathan Chadwick to Retire
• FullPAC Launches the “Final Push” of its Regulation A+ Offering Ahead of the Midterm Elections